Cheap Cialis Blogger | Search results for "sciences"

Hydrogen’s slow lane to reality A fount of starry-eyed futurists embrace been gloss us being the elapsed 30 years this hydrogen bolster cells are the breed of the thinkable, but the branch is not workable their recto. ... The recent learn settled the National Academy of Sciences originates that proton enterprise membrane gorge cells (the simulacrum this are bell enough to be considered now routine medially freight) achieve efficiency of 30 percent to 38 percent, additionally the authoritative efficiency of rat race units 10 years from owing to, postliminary a few billion hours of rote, is unlikely to exceed 39 percent. Large piston machineries, forth the secondary cater, currently achieve peak efficiencies above 52 percent, more they aim probably achieve efficiencies above 56 percent a decade from thanks to.

Tags: percent, cell, achieve, efficiency, efficiencies

Biohealthmatics.com's Daily News Digest The latest health informatics news from Biohealthmatics.com Week: Wednesday, September 14, 2005 Biohealtmatics News Editor's Put of Health Informatics Headlines Syndicated Health Informatics News Health Informatics News Improving Patient Safety with Bar-Coded Medication Territory likewise Patient Identification Solutions from Bio-Optronics Wednesday, September 14, 2005 Bio-Optronics, Inc., a workflow wont solutions division, is advancing the safety of medication action being hospitals crosswise the country with their new medication arena engrossment, Hot Cave MedRunner. ... Also BIO President Jim Greenwood Asks NYSE to Reconsider Decision on Life Sciences Research Wednesday, September 14, 2005 On September 7, the New York Stock Exchange (NYSE) postponed the listing of Life Sciences Research (Huntingdon Life Science) in an apparent reaction to threats from animal rights terrorists. ... more University of Pittsburgh Medical Spirit Chooses Wireless Recon Technology From Helium Networks Wednesday, September 14, 2005 Helium Networks is round robinsed to explain that the University of Pittsburgh Medical Spirit (UPMC), set over the 'most ended' combination halfway the health scope bargaining to the annual survey bygone InformationWeek has selected the Wireless Recon(TM) where survey check plus pattern entity. ... Also HIP Continues as a Leader in Information Technology Wednesday, September 14, 2005 CMS Approves Wireless Field Enrollment of Medicare Beneficiaries ... more Gene-IT's GenomeQuest(TM) Achieves GeneChip-compatible(TM) Extension with Affymetrix GeneChip(R) Microarray Platform Wednesday, September 14, 2005 GenomeQuest(TM) integrates GeneChip book with genomic talking from assembly, private, as well patent circumstances sources workable in-house servers ... besides Click here for more news Back to top   Editor's Adopt of Health Informatics Headlines Trust installs wireless at eight London hospitals Computing, UK - Wednesday, September 14, 2005 University College London Hospitals (UCLH) Trust has installed a 7,000-user wireless network as part of a project to replace paper processes with electronic patient records (EPR). ... Comments (0) Medicine Slow to Modernize Recordkeeping Ocala.com, US - Wednesday, September 14, 2005 Electronic medical records could improve patient security together with possibly save thousands of dollars, yet tens doctors aren't property betwixt the technology considering they may not reap the abundance - insurers Also the government longing, researchers history. ... Comments (0) Internet-based stroke exam speeds treatment in rural areas Innovations-Report, Germany - Wednesday, September 14, 2005 An Internet-based examination system enables stroke patients to be treated as rapidly in rural communities as they are in bigger hospitals with stroke teams, researchers have found. ... Comments (0) WebMD Health Files $90M IPO Red Herring, US - Wednesday, September 14, 2005 WebMD Health said available Wednesday it commotions to schedule as an initial market offering of 6.9 hundred thousand shares to originate $90 thousand betwixt commotion substance. ... Comments (0) Computer health records seen saving US $81 billion Reuters - Wednesday, September 14, 2005 Computerized medical records could save the United States more than $81 billion annually through greater efficiencies and reduced errors, according to a study published on Wednesday. ... Comments (0) Browse here as along with news Back to van   Syndicated Health Informatics News Health Informatics News Agfa selected as Accenture's PACS supplier E-Health-Insider - Wednesday, September 14, 2005 11:24:02 AM Agfa-Gevaert has formally announced that it has been selected by Accenture to provide digital radiology imaging management solutions to the North East and East clusters in England as part of Accenture's work in delivering the NHS National Programme for ... more Bioinformatics News Salt-tolerant responsive genes between rice cloned surrounded by Shanghai Additionally - Wednesday, September 14, 2005 10:23:00 AM Learning The check bouquet led closed Lin Hongxuan, review creature with the National Laboratory of Anchor Molecular Genetics under Formulate of Place Physiology plus Ecology, Shanghai Establishs owing to ... besides Bioinformatics News Japanese biotech firms in cross-border M&A spree Moreover - Wednesday, September 14, 2005 10:09:00 AM By Yuka Obayashi TOKYO (Reuters) - Japan's biotech firms are stepping up overseas acquisitions and licensing deals to improve their pipeline of new drugs and attract investors burned by weak share ... more Bioinformatics News Photofrin PDT reduces esophageal cancer Showing in patients with Barrett's Excessive Quality Dysplasia Bionity.com - Wednesday, September 14, 2005 9:04:33 AM Axcan Pharma Inc. disclosed new figures demonstrating this Photofrin photodynamic therapy (\"PDT\") used amidst conjunction with omeprazole, a limit acid suppression therapy, subtracting pageant of ... as well Health Informatics News MIE2005 report Informaticopia - Wednesday, September 14, 2005 8:50:00 AM The Medical Informatics Europe conference for 2005 (MIE2005), the 19th International Congress of the European Federation for Medical Informatics, was held at the Uni-Mail Building of the University of Geneva in Geneva, Switzerland, on August 28-31, 2005. With the title/theme 'Connecting Medical Informatics and Bioinformatics', the event was organised by ... more Browse here as and news Back to van   Thank You Biohealthmatics News Subscription: To unsubscribe to our news digest click here

Tags:

From a story in today's WaPo, I learned that Bayer has withdrawn it's poultry anitbiotic Baytril from the market. This marks the end of a five-year battle with the FDA over the drug. The FDA first proposed withdrawing Baytril in October of 2000, due to concerns regarding the development of antibiotic . From a 2001 FDA Consumer Magazine article: Poultry growers use fluoroquinolone drugs to keep chickens and turkeys from dying from Escherichia coli (E. coli) infection, a disease that they could pick up from their own droppings. But the size of flocks precludes testing and treating individual chickens--so when a veterinarian diagnoses an infected bird, the farmers treat the whole flock by adding the drug to its drinking water. While the drug may cure the E. coli bacteria in the poultry, another kind of bacteria--Campylobacter--may build up resistance to these drugs. And that's the root of the problem. People who consume chicken or turkey contaminated with fluoroquinolone-resistant Campylobacter are at risk of becoming infected with a bacteria that current drugs can't easily kill. Campylobacter is the most common bacterial cause of diarrheal illness in the United States, according to the Centers for Disease Control and Prevention. It's estimated to affect over 2 million persons every year, or 1 percent of the population. Commonly found in chickens, Campylobacter doesn't make the birds sick. But humans who eat the bacteria-contaminated birds may develop fever, diarrhea, and abdominal cramps. In people with weakened immune systems, Campylobacter can be life-threatening. Eating undercooked chicken or turkey, or other food that has been contaminated from contact with raw poultry, is a frequent source of Campylobacter infection. Not washing utensils, countertops, cutting boards, sponges, or hands after coming into contact with raw poultry can also spread the bacteria and cause infection. People infected with Campylobacter may be prescribed a fluoroquinolone--which may or may not work. But the damage doesn't stop there. "Cross-resistance occurs throughout this class of drugs," says Stephen F. Sundlof, DVM, PhD, director of CVM. "So resistance to one fluoroquinolone can compromise the effectiveness of all fluoroquinolone drugs." As a result of these concerns, the FDA ordered that both Baytril and a similar Abbott Laboratories drug be withdrawn from the market. Abbott complied with the ruling, and Bayer appealed. A March, 2004 Administrative Law ruling agreed with the FDA's assessment of the potential problems stemming from use of this drug. Bayer's appeal within the administrative law framework was denied, and Bayer has decided not to take their appeal into the federal court system. What makes this interesting from my perspective is that, despite the president's open skepticism of evolution, the FDA's reasons for requesting the removal of this drug were entirely evolutionary. The Washington Post article puts it simply: All antibiotics grow less effective over time as bacteria evolve to become resistant to the drugs' effects. Experts say wider use of an antibiotic -- by either animals or people -- leads to a speedier development of resistance. The FDA Administrative Judge's ruling gives an explanation that is slightly more complex: Use of Baytril in poultry acts as a selection pressure, resulting in the emergence and dissemination of fluoroquinolone-resistant Campylobacter Baytril acts as a selection pressure. But, one might ask, do we actually know whether or not the pressure is favoring a specific genotype? Is there a "resistance gene" in this bacteria? If so, do we know the sequence of mutations that lead to this? In this case, we do. Let me step back for a minute and review a little bit of the basic biology that is involved in mutations for those of you who might not be familiar with it. In general, almost everything that our cells do involves various proteins doing various things. Our cells make the proteins based on the instructions found in our DNA. Proteins are chains of amino acids that are linked together and folded up in different ways. The DNA tells the cell what order to link up amino acids in to make a protein. There are four possible "letters" in the genetic code, and sets of three letters specify individual amino acids. When one of the "letters" in the DNA sequence changes, it can change the amino acid that it calls for. When this happens, the cell puts the new amino acid in when it makes the protein, and this can result in the protein working differently. (For more information on this, follow the links in the paragraph.) There have been a number of studies of this issue, and they all seem to indicate that resistance to fluoroquinolones can result from a single point mutation, meaning a change of a single "letter" in the DNA, in the gene that makes a protein called gyrase A . Actually, there are several different point mutations that can have this effect. Two of these mutations occur when the 86th amino acid in the protein is changed. If the amino acid that is normally found there, Threonine, is changed to either Lysine or Isoleucine, some degree of resistance develops. Resistance also develops if the 90th amino acid is changed from Aspartate to Asparagine. Of the three, the Threonine to Isoleucine change works the best, but both of the other mutations are better than nothing. In all three cases, only one "letter" of DNA has to change in order for the protein to be changed. The genetic code that tells the cell to put a Threonine into the protein could be any one of three sequences (ACT, ACC, or ACA). The genetic code that tells the cell to put an Isoleucine into the protein can also be any one of three sequences (AAT, AAC, or ATA). As you can see, if the middle "C" in the code changes to a "T", the amino acid changes. If "ACA" is changed to "AAA", the Threonine is replaced with Lysine. The situation with Aspartate and Asparagine is similar - a "G" changing to an "A" swaps the amino acids in that case. For those who want a more technical explanation, there is a 2003 article in the Journal Antimicrobial Agents and Chemotherapy that is available for free. The full reference can be found at the bottom of this post. Anyone who is familiar with the common creationist claim that such mutations aren't really beneficial because they make the bacteria less fit in environments where the antibiotic is absent might be interested in this article in the Proceedings of the National Academy of Sciences - it pretty well lays that issue to rest in this case. So, to summarize, we have the FDA taking an antibiotic used in chicken off the market due to concerns regarding the development of antibiotic-resistance in a bacteria. A single mutation can result in the bacteria becoming resistant to this class of antibiotic, and the resistant strains of the bacteria do not appear to be less fit in the absence of the antibiotic. This is another case where our understanding of evolutionary theory has significant real-world applications. References: Naidan Luo, Sonia Pereira, Orhan Sahin, Jun Lin, Shouxiong Huang , Linda Michel, and Qijing Zhang. 2005. Enhanced in vivo fitness of fluoroquinolone-resistant Campylobacter jejuni in the absence of antibiotic selection pressure. PNAS. Vol 102 p. 541 Naidan Luo, Orhan Sahin, Jun Lin, Linda O. Michel, and Qijing Zhang. 2003. In Vivo Selection of Campylobacter Isolates with High Levels of Fluoroquinolone Resistance Associated with gyrA Mutations and the Function of the CmeABC Efflux Pump. Antimicrobial Agents and Chemotherapy. Vol 47, p. 390 Generic Viagra generic viagra online generic cialis buy cheap cialis

Tags:

Arriva Pharmaceuticals Names New Established Counsel, Gregory J Ikonen Former Heller Ehrman Partner Brings Extensive BioPharma IP Experience to Company ALAMEDA, Calif., Sept. 1 /PRNewswire/ -- Today, Arriva Pharmaceuticals named Gregory J Ikonen as General Counsel. Mr. Ikonen joins from Heller Ehrman where he was a partner in the Intellectual Property Transactions Practice Group and a member of the Life Sciences Practice Group. He assumes his position as Arriva enters its next phase of growth. Mr. Ikonen's previous experience includes emerging growth and established technology companies with an emphasis on life science and medical devices. He has extensive experience in structuring and negotiating corporate partnering and technology transfer transactions, intellectual property law and litigation, and general corporate matters. Prior to joining Heller Ehrman, Mr. Ikonen was a director at Venture Law Group. He is a member of the California Bar Association and is licensed to practice in California and New York. He graduated from the University of Michigan with a B.S. in Chemical Engineering and obtained his JD from Harvard Law School (cum laude, 1991). "Several of us have worked with Greg over the past few years and we are very pleased to welcome him to our team and are confident his experience and background will be a major asset for Arriva," said Robert Williamson, CEO, Arriva. About Arriva: Arriva Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on developing anti-inflammatory therapies for treating respiratory diseases. The company's areas of therapeutic focus are: hereditary emphysema, chronic obstructive pulmonary disease (COPD) including smoking-related emphysema, cystic fibrosis and other respiratory indications. Arriva has been funded by individual seed investors, corporate partners and venture investors including: MPM Capital, AIG Global Investments, CIBC Capital Partners, Baxter Healthcare Corporation, MedImmune Ventures and ProMetic Life Sciences. Company headquarters are in Alameda, California. For additional information please visit: http://www.arrivapharm.com/ Source: Arriva Pharmaceuticals, Inc. CONTACT: Matthew Dean, +1-510-337-7883, mdean@arrivapharm.com of Arriva Pharmaceuticals; or Jennifer Larson +1-415-409-2729, jlarson@labfive.com for Arriva Pharmaceuticals Web site: http://www.arrivapharm.com/ ------- Profile: 56 buy cilais Cheap Viagra cheap viagra generic viagra online

Tags: arriva, pharmaceuticals, ikonen, partner, company

There's conjointly developing news credible a interpretation we first attained here onward January 2, 2007, the FAMU College of Pharmacy furthermore Pharmaceutical Sciences has been allocate under probationary scope as June 30, 2008. The accreditation of the six-year doctor of pharmacy gradation continues. The Accreditation Council Because Pharmacy Wisdom, which placed the college onward criterion, said this at intervals the comparisons start up to non-compliant were strategic planning, curriculum check, statistics of adequate capability to betide lacks along appropriate financial property. Surrounded by a Jan. 30 memo to the FAMU bureau of trustees, Interim President Castell Bryant stated, \"The accreditation bout granted being the Doctor of Pharmacy row extends meanwhile June 30, 2008, under Probationary Leeway, a juncture of solo tempo, which is lower than the definitive six-year cycle. This accreditation age reflects ACPE's ending thought through the Doctor of Pharmacy behavior at the College. Decipher along: Pharmacy hopeful probing Pharmacy facing search Showdown enclosed by O-town Lewis-v-Bryant, the back specification Bryant-vs-Pharmacy faculty Pharmacy faculty issue resolution of discontent Castell to pharmacy faculty: Yall overpaid! Labels: Pharmacy Cheap Viagra generic cialis Generic Viagra cialis

Tags: pharmacy, accreditation, college, bryant, doctor

By, IRIN PlusNews, April 25, 2007 Malaria is reclaiming the world's attention after years of playing second fiddle to HIV. Experts are now convinced that the disease plays a greater role in the AIDS pandemic than was previously thought. "The disease has for too long been considered a separate health concern to HIV... it is high time that malaria was shown the same global dedication as HIV/AIDS," Malama Muleba, executive director of the Zambia Malaria Foundation (ZMF), told IRIN/PlusNews. He acknowledged that growing scientific interest in the dangers of co-infection between the two diseases had helped put Malaria back in the spotlight. Although the two infections have formed a deadly combination in most of sub-Saharan Africa for decades, earlier studies were not able to confirm the impact of malaria on HIV and vice versa. Now, the findings of a recent study by the University of Washington's Public Health Sciences (PHS) research division show that malaria fuels the spread of HIV, while HIV has also boosted malaria-infection rates. Published in the December 2006 issue of Science, a leading research journal, the study showed that because malaria increases the viral load [amount of HIV] in an HIV-positive person, it also makes HIV more transmissible to a sexual partner. "Malaria has contributed considerably to the spread of HIV by increasing HIV transmission probability per sexual act," one of the study's co-authors, Dr Laith Abu-Raddad, confirmed in the Science article. The researchers found that, conversely, HIV also plays a role in the spread of malaria, as the weakening of the immune system by the HI virus fuels a rise in adult malaria-infection rates, and may have facilitated the expansion of malaria in Africa. The World Health Organisation (WHO) estimates that over 90 percent of the one million global malaria deaths per year occur in African countries, while the UN Children's Fund (UNICEF) says malaria is the leading cause of death in many parts of Africa, with one child dying from the disease every 30 seconds. On the occasion of Africa Malaria Day, on 25 April each year, the Roll Back Malaria Partnership, an initiative created in 1998 by WHO, UNICEF, the UN Development Programme and the World Bank, announced its target of securing a 50 percent success rate for malaria grant applications to the Global Fund to Fight AIDS, Tuberculosis and Malaria, the largest international funder of malaria programmes. "Malaria control works ... if the richest nations expand their support at the [upcoming] June G8 meeting in Germany, we can dramatically reduce the one million deaths a year from malaria," said Michel Kazatchkine, executive director of the Fund, in a statement on Africa Malaria Day. Over 90 percent of the one million global malaria deaths per year occur in Africa. In Namibia, where the HIV prevalence rate is close to 20 percent and malaria accounts for almost nine percent of all hospital deaths, the Social Marketing Association (SMA), a non-governmental organisation, also stressed the importance of ongoing support in combating the two diseases. The SMA's regional coordinator, Mauritius Ngishindwa, told IRIN/PlusNews, "It [the malaria/HIV co-infection findings] is scary, but also very important because malaria, in a sense, had been sidelined by the AIDS pandemic ... it warrants more than an isolated annual event to really address the two diseases." Echoing these sentiments, Malama Muleba, director of the Zambia Malaria Foundation, said events such as World AIDS Day and Africa Malaria Day should be ongoing initiatives, as infections and deaths by both diseases were a daily occurrence. "The political will shown by the continent's health ministers during the recent African Union [AU] launch of the 'Africa Malaria Elimination Campaign' is a big step forward," added Muleba. During the third session of the AU conference of health ministers, held in South Africa from 9 to 13 April this year, delegates committed themselves to reducing malaria morbidity and mortality by up to 75 percent by 2015 through universal access to prevention and control interventions. hh/ks/he Source: http://www.plusnews.org/Report.aspx?ReportId=71802

Tags: malaria, hiv, africa, disease, year

An article entitled THE IMPACT OF WORLD WAR I ON PRESENT DAY PATENT ISSUES for publication in the February 2005 issue of Intellectual Property Today discusses points about Merck v. Integra. Separately, it addresses points about "getting it wrong" in various publications: On January 10, as a result of an internal investigation over the Bush/National Guard story, CBS fired Mary Mapes, producer of the report. Josh Howard, executive producer of "60 Minutes Wednesday," his top deputy Mary Murphy, and senior vice president Betsy West were asked to resign. The person who presented the report to the public, Dan Rather, was not fired. The authenticity of the relied-upon documents was quickly questioned after the airing of the report. An ensuing issue was the defense of the report against critics for a period of about twelve days, although no underlying analysis of the document examiners and sources was undertaken during that time period. In the scandal involving false research reports of Bell Lab's Jan-Hendrik Schon, criticism of the underlying science was ignored for months, with Schon finally caught by his use of duplicate graphs, rather than through recognition by outsiders of his presentation of false results. Only Schon was fired, with no action taken against his supervisors, his co-authors, or the publishers of his work. Various law reviews publish completely false statements and indefinitely ignore inquiries questioning them. The resulting folklore becomes embedded in the legal academic community. ***** Speaking of law reviews, many discuss the Merck v. Integra case. In 30 Wm. Mitchell L. Rev. 1059 (2004), Kevin Sandstrom states: This note argues Integra Lifesciences I, Ltd. v. Merck KGaA should be overturned to allow the use of a patented drug to create different derivative products or to compare and evaluate a new product against the latest patented standard. Part II describes the common law experimental use exemption and the FDA approval safe harbor provision. n11 Part III reviews the facts, holding, and dissent in Integra. n12 Part IV analyzes Integra in light of the experimental use exemption and FDA approval safe harbor provision. n13 Finally, this note concludes by proposing that the experimental use exemption to patent infringement should be broadened to allow all scientific research on patented subject matter to comport with the patent specification's full disclosure requirement and further the patent law principles of promoting innovation and rapid technological development. n14 In 2004 Wis. L. Rev. 81, Katherine J. Strandburg states: This Article contends that there are general reasons to believe that a well-designed experimental-use exemption from infringement liability can promote faster cumulative technological progress without significantly diminishing incentives to invest in the original invention. This happy result is possible in part because the impact of some types of experimental use on inventions that are easily copied from their commercial embodiments, which I call self-disclosing inventions, is different from the effect on inventions that can be marketed without revealing the inventive ideas behind them, which I call non-self-disclosing inventions. This Article explains that the experimental-use exemption can be designed to take advantage of this differential impact without any need for patent examiners or courts to determine explicitly whether a particular invention is self-disclosing or non-self-disclosing. (...) This Article supports Mueller's proposal [76 Wash. L. Rev. 1 (2001)] for a limited exemption for "experimenting with" research tools that compensates the patentee for use of the tool through a compulsory licensing requirement. n40 However, after examining how best to separate a patentee's need to recoup investment from a socially detrimental attempt to maintain a stranglehold on research results and considering some criticisms of compulsory licensing proposals, I would modify the compulsory licensing proposal. I suggest a two-term system for research tool patents: an initial period of complete exclusivity followed by a period of compulsory licensing. *** Rochelle Dreyfuss in 46 Ariz. L. Rev. 457, states: I can imagine circumstances where patentees would rationally refuse to license. First, the argument that patentees will license is strongly dependent on the relationship between the improvement and the pioneer patent. Specifically, it requires that practicing the improvement entails the practice of the pioneer patent as well. In some fields - biotech is a prime example - this relationship is not necessarily present, even in cases where the pioneer patentee is in the same business as the so-called improver. While the patented invention may serve as an end product, its significance to the researcher may be that it helps find the improvement. Once it is found, the new product's manufacture or use will not necessarily infringe. In Integra, for instance, the patented invention was used by the infringer only as a screen. Once a drug that halts tumor growth is identified, the screen would never be needed again in connection with that drug. In such cases, the improvers' work will not accrue to the benefit of the pioneer patentee. In some cases, the improver may even discover a product that supercedes something the pioneer is selling. Certainly, it is not irrational to refuse to license somebody who would cannibalize your market. Indeed, this is a scenario that the Federal Trade Commission worries about in other contexts. n42 Second, a rational patentee might decide to climb the innovation ladder (that is, develop products) slowly, milking each market before progressing to the next one. Licensing others could interfere with this plan. Again, this concern is familiar. It has surfaced in patent cases from time to time. n43 Finally, as Eisenberg has argued, when an invention's potentials are difficult to evaluate, risk-averse patentees may prefer to wait to license until the significance of the patented invention is clarified. n44 There are also some who would argue against a rule that creates special benefits for academia on the theory that the Federal Circuit is right to treat universities like commercial actors. Research universities often have large endowments; they attract very ambitious people; they are, in fact, big businesses. Again, I do not agree. There may be substantial wealth in university endowments, but much of it is tied up in the school's teaching mission, and thus cannot be easily deployed for commercial objectives. Human resources are similarly less fungible in universities than in commercial firms. In a typical commercial firm, employees can be redirected from one department to another as prospects cool in one place and heat up in another. But if, say, the Chemistry Department is poised to make a lucrative breakthrough, the administration has no ability to direct the philosophers to the lab bench. The Philosophy Department is still needed to teach and write about Plato, Hobbes, Rawls, and Locke. (...) Of course, my approach also has problems. Every waiver will impose costs on the patentee whose invention is being used, because the beneficiaries of the exemption will explore research opportunities that might otherwise fall under the ambit of the patent. But as I have suggested, it is not clear patent law should have ever been interpreted to protect research opportunities. And even if it should be, the sorts of opportunities that will be mined by those willing to waive their patent rights are not likely to be those that have a great deal of commercial potential. Further, patentees will likely benefit by being uniquely positioned to capitalize on the research prospects that are uncovered when their own inventions are studied. Another question is whether anyone would ever file a waiver. Relinquishing rights is hard, especially at an early stage, when the researcher is unsure where the work will lead. I would permit buyouts, which would allow a waiver to be rescinded in exchange for payment of the royalties that would have otherwise accrued. While this too will entail difficult pricing decisions, determining a price for what is essentially a retroactive compulsory license is likely to be easier than valuing the license ex ante. Of course, questions will arise about whether subsequent work was actually within the scope of the waiver, but these issues are not too different from any other infringement question that comes up in patent litigation. The university setting will also create some difficulties. Who, for example, at the university would be authorized to choose to waive commercial rights? Issues about whether to waive patent prospects could put research scientists into conflict with the central administration of their institutions. In sum, mine is far from a perfect plan. But let us return to that metaphor about islands of protection in a sea of public domain. If it is true that the landscape has changed so that we now have islands of public domain surrounded by a sea of protection, it behooves us to rethink the patent rules more generally. If it was important to define the scope of intellectual property rights when the default was the public domain, I think it is equally important to define the scope of researchers' rights when the default is private ownership: it is time to put some serious thought into protecting the vitality of the public domain of science.

Tags: patent, invention, research, patentee, exemption

from Michael Dobbs of the Washington Post on Wed., Jan. 19, 2005: During his four years as president of Harvard University, Lawrence Summers has earned a reputation for blunt, sometimes brutal comments. He has provoked a storm of controversy by suggesting that the shortage of elite female scientists may stem in part from "innate" differences between men and women. "I felt I was going to be sick," said Nancy Hopkins, a biology professor at Massachusetts Institute of Technology, who listened to part of Summers' speech Friday [Jan. 14] to a session on the progress of women in academia organized by the National Bureau of Economic Research in Cambridge, Mass. Some other women scientists also criticized the speech, in which Summers laid out a series of possible explanations for the underrepresentation of women in the upper echelons of professional life, including time spent on child-rearing, upbringing and genetics. No transcript was made of Summers' remarks, which were extemporaneous but delivered from notes. Summers' remarks were first reported by the Boston Globe in Monday's [Jan. 17] editions. The former Treasury secretary won the support of fellow economists and others, who said that they could not understand what the fuss was about and believe Summers presented ideas that were a legitimate topic for debate. "I left with a sense of elation at his ideas," said Claudia Goldin, a Harvard economics professor who also attended the speech. "I was proud that the president of my university retains the inquisitiveness of an academic." **** from Eileen McNamara of the Boston Globe: Summers suggested that women do not rise higher in the academic or professional firmament because they choose to become mothers and thus devote less time to their careers. "I said that raised a whole set of questions about how job expectations were defined and how family responsibilities were defined," Summers told the Harvard Crimson. [He did not return my call.] "But I said it didn't explain the differences [in the representation of females] between the sciences and mathematics and other fields." Why doesn't it? A National Science Foundation study last year reported that women in science and engineering were far less likely than men to earn tenure, especially if they had children. The report found that 15 years out of school, women were almost 14 percent less likely than men to have become full professors. Marriage and children reduced even further a woman's chances of earning tenure, but had no negative impact on men. That sounds like a cultural, not a biological, problem to me. Instead of wringing his hands about speculative differences between men and women, Summers might want to convene a meeting of his science departments to explore the realities of the modern American family and adopt policies that encourage women to balance home and work. Mentor women. Provide child care. Encourage flex-time. Stop the tenure clock during pregnancy or maternity leave. The academy is tailor-made for just such experimentation. Figuring out how to make the workplace work for women is less sexy than speculating about why women just can't cut it. Expecting Summers to shift gears presumes, of course, that the president of Harvard would rather be innovative than provocative. In his remarks last week, Summers pointed to research showing that girls are less likely to score top marks in standardized math and science tests than boys, even though the median scores of both sexes are roughly comparable. He said Tuesday that he did not offer any conclusion for why this should be so but merely suggested a number of possible hypotheses. end Globe ****** Mr. Summers received a B.S. degree from the Massachusetts Institute of Technology in 1975 and a Ph.D. from Harvard University in 1982. He was Professor of Economics at Harvard from 1983-1993. ***** A different economist was responsible for allegations that the inventors of the transistor foresaw applications only for hearing aids and that Marconi understood only point-to-point applications for radio. Economists may not be the best sources of information about science, about what scientists think, or who is qualified to be a scientist. Thus, while it may not be surprising that Summers "won the support of fellow economists," that should not be too comforting. ****** Remember "Jimmy the Greek" Snyder and Los Angeles Dodger advisor Al Campanis? Maybe it's time for Summers to go. **** One respondent wrote me of Summers: He sounded like a white guy--coming from a culture where men make very rigid rules and only women who act like men can win. **** In a column "You can't say that at Harvard," (eg, Trenton Times, A13, Jan. 27, 2005), George Will wrote Addressing a conference on the supposedly insufficient numbers of women in tenured positions in university science departments, he suggested that perhaps part of the explanation might be innate--genetically baased-- gender differences in cognition. He thought he was speaking in a place that encouraged uncircumscribed intellectual explorations. (...) He was at Harvard, where he is president. Since then he has become a serial apologizer and accomplished groveler. buy cheap cialis generic viagra online cheap viagra cheap cialis

Tags: summers, women, harvard, men, science

Datamonitor's Global Pharmaceuticals, Biotechnology & Deal Sciences global pharmaceuticals, biotechnology & stint sciences clientele. It mires detailed portfolio imaginable transaction tier additionally segmentation, conjointly textual itemization of the key trends along competitive landscape, demographic annotation, along with characters of the leading companies. Estate * Absorbs an executive breakdown still file on use, quarto additionally segmentation * Finds textual failure of the rat race's customers, competitive... Additionnal reward regarding that public : Global Pharmaceuticals, Biotechnology & Tide Sciences

Tags: global, biotechnology, sciences, pharmaceuticals, textual

generic online Generic Viagra buy cheap cialis viagra

Tags: